Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Clozapine

FDA-approved product (tablet, oral), marketed as Clozapine, Clozaril, Fazaclo Odt and 1 more.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Clozapine
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Psychosis
  • Schizoaffective disorder
  • Schizophrenia

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Diazepines, oxazepines, thiazepines and oxepines
FDA pharmacologic class
Atypical Antipsychotic FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis, MRSA and E. coli. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA42.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli48.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae19.7% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis63.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Clozapine in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.0 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-6.7 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-7.7 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-7.6 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Clozapine with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • ZR001 Chemogenetics Gene Therapy Study in Patients With Parkinson's Disease

    NCT07718659 · start 2026-12-01

    Registered record
    Registry ID
    NCT07718659
    Conditions
    Parkinson's Disease (PD); Parkinsonian Disorders
    Interventions
    ZR001
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Not yet recruiting
    Start
    2026-12-01
    Completion
    2030-12-01
    Enrolment
    8

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionParkinson's Disease (PD); Parkinsonian Disorders
    InterventionZR001
    PhasePhase 1
    Registry statusNot yet recruiting

  • Intensified Pharmacological Treatment for Schizophrenia, Major Depressive Disorder and Bipolar Depression After a First-time Treatment Failure

    NCT05603104 · start 2025-04-27

    Registered record
    Registry ID
    NCT05603104
    Conditions
    Schizophrenia and Related Disorders; Major Depressive Disorder; Bipolar Depression
    Interventions
    Clozapine; Esketamine Nasal Product; Escitalopram; Sertraline; Venlafaxine; Lithium; Valproate acid; Quetiapine; Second-line Antidepressants; Second-line Antipsychotics; Ketamine Hydrochloride; Esketamine hydrochloride; Bupropion
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Recruiting
    Start
    2025-04-27
    Completion
    2028-06-30
    Enrolment
    1,254

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia and Related Disorders; Major Depressive Disorder; Bipolar Depression
    InterventionClozapine; Esketamine Nasal Product; Escitalopram; Sertraline +9 more
    PhasePhase 3
    Registry statusRecruiting

  • Evaluating the Effect of the STEP@STAH Semaglutide Protocol on the Physical Health Measures of Atypical Antipsychotic-Treated Patients

    NCT06754163 · start 2025-01-01

    Registered record
    Registry ID
    NCT06754163
    Conditions
    Obesity and Obesity-related Medical Conditions; Psychiatric Disorders
    Interventions
    Semaglutide in combination with a healthy lifestyle intervention (diet and exercise)
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Active not recruiting
    Start
    2025-01-01
    Completion
    2027-12-30
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionObesity and Obesity-related Medical Conditions; Psychiatric Disorders
    InterventionSemaglutide in combination with a healthy lifestyle intervention (diet and exercise)
    PhasePhase 4
    Registry statusActive not recruiting

  • Magnetic Seizure Therapy for Psychotic Disorders

    NCT06581302 · start 2024-09-01

    Registered record
    Registry ID
    NCT06581302
    Conditions
    Psychotic Disorders
    Interventions
    Magnetic seizure therapy by Magnetic stimulator; Antipsychotic medications (such as olanzpine, risperidone, aripiprazole, quetiapine, amisulpride, etc)
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Recruiting
    Start
    2024-09-01
    Completion
    2025-12-30
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPsychotic Disorders
    InterventionMagnetic seizure therapy by Magnetic stimulator; Antipsychotic medications (such as olanzpine, risperidone, aripiprazole, quetiapine, amisulpride, etc)
    PhaseNot applicable
    Registry statusRecruiting

  • Metabolic Effects of Adjunctive Lumateperone Treatment in Clozapine-Treated Patients With Schizophrenia

    NCT06174116 · start 2024-04-02

    Registered record
    Registry ID
    NCT06174116
    Conditions
    Schizophrenia; Schizo Affective Disorder
    Interventions
    Lumateperone; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Recruiting
    Start
    2024-04-02
    Completion
    2027-03
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia; Schizo Affective Disorder
    InterventionLumateperone; Placebo
    PhasePhase 4
    Registry statusRecruiting

  • Clozapine Hematological Monitoring Regulatory Compliance Assessment in Psychiatry

    NCT06610500 · start 2023-05-16

    Registered record
    Registry ID
    NCT06610500
    Conditions
    Schizophrenia; Agranulocytosis
    Interventions
    Questionnaires
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2023-05-16
    Completion
    2023-09-12
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia; Agranulocytosis
    InterventionQuestionnaires
    PhaseNot recorded
    Registry statusCompleted

  • Clozapine Therapy Sample Collection - Method Comparison Study

    NCT05422131 · start 2022-11-12

    Registered record
    Registry ID
    NCT05422131
    Conditions
    Patients Prescribed Clozapine
    Interventions
    MyCare Insite Clozapine Test
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2022-11-12
    Completion
    2023-05-16
    Enrolment
    153

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPatients Prescribed Clozapine
    InterventionMyCare Insite Clozapine Test
    PhaseNot recorded
    Registry statusCompleted

  • Clozapine for the Prevention of Violence in Schizophrenia: a Randomized Clinical Trial

    NCT05208190 · start 2022-03-17

    Registered record
    Registry ID
    NCT05208190
    Conditions
    Schizophrenia; Schizoaffective Disorder
    Interventions
    Clozapine; treatment as usual
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Recruiting
    Start
    2022-03-17
    Completion
    2028-12-31
    Enrolment
    280

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia; Schizoaffective Disorder
    InterventionClozapine; treatment as usual
    PhasePhase 4
    Registry statusRecruiting

  • CLOZAPINE Response in Biotype-1

    NCT04580134 · start 2022-03-01

    Registered record
    Registry ID
    NCT04580134
    Conditions
    Schizophrenia; Schizoaffective Disorder; Bipolar 1 Disorder
    Interventions
    clozapine; risperidone
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Recruiting
    Start
    2022-03-01
    Completion
    2027-04-30
    Enrolment
    524

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia; Schizoaffective Disorder; Bipolar 1 Disorder
    Interventionclozapine; risperidone
    PhasePhase 4
    Registry statusRecruiting

  • Efficacy of SMOF Lipid in the Management of Acute Poisoning With Clozapine

    NCT06413589 · start 2022-01-01

    Registered record
    Registry ID
    NCT06413589
    Conditions
    Acute Poisoning
    Interventions
    SMOF lipid 20%; standard treatment for clozapine toxicity
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2022-01-01
    Completion
    2023-02-28
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Poisoning
    InterventionSMOF lipid 20%; standard treatment for clozapine toxicity
    PhasePhase 2
    Registry statusCompleted

  • Pharmacokinetics of Clozapine and Norclozapine and the Effect of Pantoprazole

    NCT07262736 · start 2021-02-06

    Registered record
    Registry ID
    NCT07262736
    Conditions
    Healthy Volunteers - Male and Female
    Interventions
    clozapine; pantoprazole
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2021-02-06
    Completion
    2022-02-28
    Enrolment
    33

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy Volunteers - Male and Female
    Interventionclozapine; pantoprazole
    PhasePhase 1
    Registry statusCompleted

  • Bioequivalence Study in Patients With Schizophrenia by Using Clozaril 100 mg Tablet (Clozapine) and WID-CLZ18

    NCT04849026 · start 2021-01-15

    Registered record
    Registry ID
    NCT04849026
    Conditions
    Schizophrenia
    Interventions
    Clozaril 100 mg (Clozapine); WID-CLZ18
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2021-01-15
    Completion
    2022-08-14
    Enrolment
    33

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia
    InterventionClozaril 100 mg (Clozapine); WID-CLZ18
    PhasePhase 1
    Registry statusCompleted

  • Study to Compare Clozapine vs Treatment as Usual in People With Intellectual Disability & Treatment-resistant Psychosis

    NCT04529226 · start 2020-11-26

    Registered record
    Registry ID
    NCT04529226
    Conditions
    Psychosis; Intellectual Disability
    Interventions
    Clozapine; haloperidol, pimozide, olanzapine, risperidone, amisulpride
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2020-11-26
    Completion
    2025-12-30
    Enrolment
    75

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPsychosis; Intellectual Disability
    InterventionClozapine; haloperidol, pimozide, olanzapine, risperidone, amisulpride
    PhasePhase 2
    Registry statusUnknown

  • Clozapine Use Pattern in the Province of Seville

    NCT05083377 · start 2020-09-08

    Registered record
    Registry ID
    NCT05083377
    Conditions
    Schizophrenia and Related Disorders
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2020-09-08
    Completion
    2021-09-08
    Enrolment
    600

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia and Related Disorders
    InterventionNot recorded
    PhaseNot recorded
    Registry statusCompleted

  • Adjunctive Use of Fute (Flupentixol) in Multi-acting Receptor-targeted Antipsychotics Treated Schizophrenia Patients

    NCT04898270 · start 2019-12-19

    Registered record
    Registry ID
    NCT04898270
    Conditions
    Schizophrenia; Psychosis; Metabolic Syndrome; Flupentixol; Antipsychotic Agents; Central Nervous System Diseases; Clinical Therapy; Olanzapine; Quetiapine
    Interventions
    Flupentixol; Multi-acting receptor-targeted antipsychotics (MARTAs)
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2019-12-19
    Completion
    2021-04-20
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia; Psychosis; Metabolic Syndrome; Flupentixol +5 more
    InterventionFlupentixol; Multi-acting receptor-targeted antipsychotics (MARTAs)
    PhasePhase 4
    Registry statusCompleted